Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi Li, Wei Guo, Xiuqin Li, Jianguo Zhang, Moyi Sun, Zhangui Tang, Wei Ran, Kai Yang, Guilin Huang, Longjiang Li
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Dentistry RK1-715
Acceso en línea:	https://doaj.org/article/d58a102c0f7349e89574158df0039104
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d58a102c0f7349e89574158df0039104
record_format	dspace
spelling	oai:doaj.org-article:d58a102c0f7349e89574158df00391042021-11-21T12:06:33ZExpert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers10.1038/s41368-021-00145-11674-28182049-3169https://doaj.org/article/d58a102c0f7349e89574158df00391042021-11-01T00:00:00Zhttps://doi.org/10.1038/s41368-021-00145-1https://doaj.org/toc/1674-2818https://doaj.org/toc/2049-3169The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug for patients who suffered from head and neck squamous cell carcinoma (HNSCC). The basic therapeutic theories of gene therapy were totally different from the traditional ones, such as surgeries or radio- and chemotherapy, and the evaluation of treatment outcomes should also be changed simultaneously. However, there still existed a lot of misunderstandings about gene therapy, which resulted in improper administration, insufficient dosage calculation, and treatment cycles, and the treatment outcomes were unsatisfactory, especially for inexperienced oncologists or hospitals. Therefore, we will provide some practical guidance here on the gene therapy of rAd-p53 based on our previous research and experience, which focused on the basic theories and clinical issues, to answer the questions arising during the clinical of gene therapy and to accelerate the development of gene therapy for the benefit of patients bearing malignant tumors.Yi LiWei GuoXiuqin LiJianguo ZhangMoyi SunZhangui TangWei RanKai YangGuilin HuangLongjiang LiNature Publishing GrouparticleDentistryRK1-715ENInternational Journal of Oral Science, Vol 13, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dentistry RK1-715
spellingShingle	Dentistry RK1-715 Yi Li Wei Guo Xiuqin Li Jianguo Zhang Moyi Sun Zhangui Tang Wei Ran Kai Yang Guilin Huang Longjiang Li Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
description	The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug for patients who suffered from head and neck squamous cell carcinoma (HNSCC). The basic therapeutic theories of gene therapy were totally different from the traditional ones, such as surgeries or radio- and chemotherapy, and the evaluation of treatment outcomes should also be changed simultaneously. However, there still existed a lot of misunderstandings about gene therapy, which resulted in improper administration, insufficient dosage calculation, and treatment cycles, and the treatment outcomes were unsatisfactory, especially for inexperienced oncologists or hospitals. Therefore, we will provide some practical guidance here on the gene therapy of rAd-p53 based on our previous research and experience, which focused on the basic theories and clinical issues, to answer the questions arising during the clinical of gene therapy and to accelerate the development of gene therapy for the benefit of patients bearing malignant tumors.
format	article
author	Yi Li Wei Guo Xiuqin Li Jianguo Zhang Moyi Sun Zhangui Tang Wei Ran Kai Yang Guilin Huang Longjiang Li
author_facet	Yi Li Wei Guo Xiuqin Li Jianguo Zhang Moyi Sun Zhangui Tang Wei Ran Kai Yang Guilin Huang Longjiang Li
author_sort	Yi Li
title	Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
title_short	Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
title_full	Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
title_fullStr	Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
title_full_unstemmed	Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
title_sort	expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
publisher	Nature Publishing Group
publishDate	2021
url	https://doaj.org/article/d58a102c0f7349e89574158df0039104
work_keys_str_mv	AT yili expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT weiguo expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT xiuqinli expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT jianguozhang expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT moyisun expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT zhanguitang expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT weiran expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT kaiyang expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT guilinhuang expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers AT longjiangli expertconsensusontheclinicalapplicationofrecombinantadenovirushumanp53forheadandneckcancers
_version_	1718419273174482944

Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

Ejemplares similares